Trials / Completed
CompletedNCT03647124
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.
Detailed description
This is a European multinational, retrospective, non-interventional study of participants with relapsed or refractory mantle cell lymphoma (R/R MCL). Potential sites will be identified where R/R MCL participants have been treated with lenalidomide. Site inclusion will be limited to countries where lenalidomide is reimbursed for this indication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | Specified dose on specified days |
Timeline
- Start date
- 2019-03-13
- Primary completion
- 2024-01-10
- Completion
- 2024-01-10
- First posted
- 2018-08-27
- Last updated
- 2025-03-04
Locations
79 sites across 7 countries: Austria, France, Germany, Greece, Italy, Netherlands, Spain
Source: ClinicalTrials.gov record NCT03647124. Inclusion in this directory is not an endorsement.